Johnson & Johnson (NYSE:JNJ) Shares Purchased by Prospector Partners LLC

Prospector Partners LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 15.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 77,232 shares of the company’s stock after buying an additional 10,585 shares during the quarter. Prospector Partners LLC’s holdings in Johnson & Johnson were worth $11,169,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of JNJ. Oregon Pacific Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $949,000. Horan Securities Inc. grew its stake in Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock valued at $1,038,000 after acquiring an additional 90 shares during the last quarter. Strategic Financial Concepts LLC boosted its stake in shares of Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after acquiring an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at $69,859,000. Finally, KPP Advisory Services LLC grew its holdings in Johnson & Johnson by 4.7% in the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after buying an additional 515 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 4.3 %

Shares of NYSE:JNJ opened at $153.03 on Friday. The company has a fifty day moving average of $159.75 and a 200-day moving average of $155.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a market capitalization of $368.77 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, Citigroup lowered their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.